386 related articles for article (PubMed ID: 27771121)
21. Muir-Torre syndrome: case report and review of the literature.
Ang JM; Alai NN; Ritter KR; Machtinger LA
Cutis; 2011 Mar; 87(3):125-8. PubMed ID: 21488569
[TBL] [Abstract][Full Text] [Related]
22. [Muir-Torre syndrome: rare association with duodenal carcinoma].
Bacha D; Deschamps L; Sauvanet A; Couvelard A
Ann Pathol; 2009 Dec; 29(6):495-8. PubMed ID: 20005439
[TBL] [Abstract][Full Text] [Related]
23. Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy.
Landis MN; Davis CL; Bellus GA; Wolverton SE
J Am Acad Dermatol; 2011 Nov; 65(5):1054-1058.e1. PubMed ID: 21550136
[TBL] [Abstract][Full Text] [Related]
24. Retroperitoneal undifferentiated pleomorphic sarcoma having microsatellite instability associated with Muir-Torre syndrome: case report and review of literature.
Lee N; Luthra R; Lopez-Terrada D; Wang WL; Lazar AJ
J Cutan Pathol; 2013 Aug; 40(8):730-3. PubMed ID: 23672746
[TBL] [Abstract][Full Text] [Related]
25. Biallelic MYH germline mutations as cause of Muir-Torre syndrome.
Guillén-Ponce C; Castillejo A; Barberá VM; Pascual-Ramírez JC; Andrada E; Castillejo MI; Guarinós C; Molina-Garrido MJ; Carrato A; Soto JL
Fam Cancer; 2010 Jun; 9(2):151-4. PubMed ID: 19998059
[TBL] [Abstract][Full Text] [Related]
26. Synchronous gastric and sebaceous cancers, a rare manifestation of MLH1-related Muir-Torre syndrome.
Svec J; Schwarzová L; Janošíková B; Stekrová J; Mandys V; Kment M; Vodička P
Int J Clin Exp Pathol; 2014; 7(8):5196-202. PubMed ID: 25197397
[TBL] [Abstract][Full Text] [Related]
27. Muir-Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients.
Ponti G; Pellacani G; Ruini C; Percesepe A; Longo C; Mandel VD; Crucianelli F; Gorelli G; Tomasi A
Fam Cancer; 2014 Dec; 13(4):553-61. PubMed ID: 24969397
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological study of 47 cases of sebaceoma.
Bourlond F; Velter C; Cribier B
Ann Dermatol Venereol; 2016 Dec; 143(12):814-824. PubMed ID: 27836252
[TBL] [Abstract][Full Text] [Related]
29. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry.
Ponti G; Losi L; Di Gregorio C; Roncucci L; Pedroni M; Scarselli A; Benatti P; Seidenari S; Pellacani G; Lembo L; Rossi G; Marino M; Lucci-Cordisco E; Ponz de Leon M
Cancer; 2005 Mar; 103(5):1018-25. PubMed ID: 15662714
[TBL] [Abstract][Full Text] [Related]
30. BRAF/KRAS gene sequencing of sebaceous neoplasms after mismatch repair protein analysis.
Cornejo KM; Hutchinson L; Deng A; Tomaszewicz K; Welch M; Lyle S; Dresser K; Cosar EF
Hum Pathol; 2014 Jun; 45(6):1213-20. PubMed ID: 24767862
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemistry screening of sebaceous lesions for Muir-Torre syndrome in a 26-year period in a Mexican population.
Archer-Dubon C; Alvarez-Zavala B; Reyes E; Orozco-Topete R
Dermatol Online J; 2008 Dec; 14(12):1. PubMed ID: 19265614
[TBL] [Abstract][Full Text] [Related]
32. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.
Ponti G; Losi L; Pedroni M; Lucci-Cordisco E; Di Gregorio C; Pellacani G; Seidenari S
J Invest Dermatol; 2006 Oct; 126(10):2302-7. PubMed ID: 16826164
[TBL] [Abstract][Full Text] [Related]
33. MSH6 mutation in a family affected by Muir-Torre syndrome.
Kacerovska D; Cerna K; Martinek P; Grossmann P; Michal M; Ricar J; Kazakov DV
Am J Dermatopathol; 2012 Aug; 34(6):648-52. PubMed ID: 22814321
[TBL] [Abstract][Full Text] [Related]
34. Clinical and Molecular Features of Skin Malignancies in Muir-Torre Syndrome.
Simic D; Dummer R; Freiberger SN; Ramelyte E; Barysch MJ
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065301
[TBL] [Abstract][Full Text] [Related]
35. Muir-Torre syndrome.
Bhaijee F; Brown AS
Arch Pathol Lab Med; 2014 Dec; 138(12):1685-9. PubMed ID: 25427047
[TBL] [Abstract][Full Text] [Related]
36. Molecular Genetics of Sebaceous Neoplasia.
North JP
Surg Pathol Clin; 2021 Jun; 14(2):273-284. PubMed ID: 34023105
[TBL] [Abstract][Full Text] [Related]
37. Role of microsatellite instability, immunohistochemistry and mismatch repair germline aberrations in immunosuppressed transplant patients: a phenocopy dilemma in Muir-Torre syndrome.
Ponti G; Manfredini M; Pellacani G; Tomasi A
Clin Chem Lab Med; 2016 Nov; 54(11):1725-1731. PubMed ID: 27016151
[TBL] [Abstract][Full Text] [Related]
38. Fordyce granules and hyperplastic mucosal sebaceous glands as distinctive stigmata in Muir-Torre syndrome patients: characterization with reflectance confocal microscopy.
Ponti G; Meschieri A; Pollio A; Ruini C; Manfredini M; Longo C; Mandel VD; Ciardo S; Tomasi A; Giannetti L; Pellacani G
J Oral Pathol Med; 2015 Aug; 44(7):552-7. PubMed ID: 25213213
[TBL] [Abstract][Full Text] [Related]
39. Analysis of Sebaceous Neoplasms for DNA Mismatch Repair Proteins in Muir-Torre Syndrome.
Pollinger TH; Kieliszak CR; Logemann N; Gratrix ML
Skinmed; 2017; 15(4):259-264. PubMed ID: 28859734
[TBL] [Abstract][Full Text] [Related]
40. Muir-Torre syndrome and recent updates on screening guidelines: The link between colorectal tumors and sebaceous adenomas in unusual locations.
Shaker N; Shaker N; Abid A; Shah S; Shakra RA; Sangueza OP
J Surg Oncol; 2023 Dec; 128(8):1380-1384. PubMed ID: 37706607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
